--- page 1 ---
– 1 –
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited
(the “ Stock Exchange ”) and Hong Kong Securities Clearing Company Limited (“ HKSCC ”)
take no responsibility for the contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any liability whatsoever for any loss
howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined herein, capitalized terms used in this announcement shall have the
same meanings as those defined in the prospectus dated July 17, 2025 (the “ Prospectus ”)
issued by Nanjing Leads Biolabs Co., Ltd. (
ʮ̡ ) (the
“Company ”).
This announcement is for information purposes only and does not constitute an offer or an
invitation to induce an offer by any person to acquire, purchase or subscribe for any securities
of the Company. This announcement is not a prospectus. Potential investors should read the
Prospectus for detailed information about the Company and the Global Offering described
below before deciding whether or not to invest in the Offer Shares. Any investment decision in
relation to the Offer Shares should be taken solely in reliance on the information provided in
the Prospectus.
This announcement is not for release, publication, distribution, directly or indirectly, in or
into the United States (including its territories and possessions, any state of the United States
and the District of Columbia). This announcement doe s not constitute or form a part of any
offer or solicitation to purchase or subscribe for any securities in the United States or in any
other jurisdictions. The Offer Shares have not been, and will not be, registered under the
United States Securities Act of 1933, as amended (the “ U.S. Securities Act ”) or securities law
of any state or other jurisdiction of the United  States and may not be offered, sold, pledged
or otherwise transferred within the United States. The Offer Shares may not be offered, sold,
pledged or otherwise transferred within the United States, except pursuant to an available
exemption from, or in a transaction not subject to, the registration requirements of the U.S.
Securities Act. There will be no public offer of the Offer Shares in the United States. The Offer
Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule
144A under the U.S. Securities Act pursuant to Rule 144A or another available exemption
from registration under the U.S. Securities Act and (2) outside the United States in offshore
transactions in reliance on Regulation S under the U.S. Securities Act.
In connection with the Global Offering, Morgan Stanley Asia Limited and CITIC Securities
(Hong Kong) Limited act as the Joint Sponsors; Morgan Stanley Asia Limited and CLSA
Limited act as the Sponsor-Overall Coordinators and CMB International Capital Limited acts
as the Overall Coordinator.
Potential investors of the Offer Shares should note that the Overall Coordinators (for
themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their
obligations under the Hong Kong Underwriting Agreement with immediate effect upon the
occurrence of any of the events set out in the section headed “Underwriting — Hong Kong
Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination” in
the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is
currently expected to be on Friday, July 25, 2025).


--- page 2 ---
– 2 –
Nanjing Leads Biolabs Co., Ltd.
ʮ̡
(A joint stock company established in the People’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the Global
Offering
: 36,862,500 H Shares (taking into account
the full exercise of the Offer Size
Adjustment Option and subject to the
Over-allotment Option)
Number of Hong Kong Offer Shares : 16,027,200 H Shares (as adjusted after
reallocation)
Number of International Offer Shares : 20,835,300 H Shares (taking into account
the full exercise of the Offer Size
Adjustment Option, as adjusted after
reallocation and subject to the Over-
allotment Option)
Offer Price : HK$35.00 per H Share, plus brokerage of
1.0%, SFC transaction levy of 0.0027%,
AFRC transaction levy of 0.00015%
and Hong Kong Stock Exchange
trading fee of 0.00565%
Nominal value : RMB1.00 per H Share
Stock code : 9887
Joint Sponsors
Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
Joint Bookrunners and Joint Lead Managers


--- page 3 ---
– 3 –
Nanjing Leads Biolabs Co., Ltd. / ԯၪʮ̡
ANNOUNCEMENT OF FINAL OFFER PRICE AND
ALLOTMENT RESULTS
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same
meanings as those defined in the prospectus dated July 17, 2025 (the “ Prospectus ”) issued by Nanjing
Leads Biolabs Co., Ltd. (ԯၪʮ̡ ) (the “ Company ”).
Warning: In view of high concentration of shareholding in a small number of Shareholders,
Shareholders and prospective investors should be aware that the price of the H Shares could
move substantially even with a small number of H Shares traded and should exercise extreme
caution when dealing in the H Shares.
SUMMARY
Company information
Stock code 9887
Stock short name LEADS BIOLABS-B
Dealings commencement date July 25, 2025*
* see note at the end of the announcement
Price Information
Final Offer Price HK$35.00
Offer Price Range HK$31.60 – HK$35.00
Offer Shares and Share Capital
Number of Offer Shares (taking into account
the full exercise of the Offer Size Adjustment Option)
36,862,500 H Shares
Number of Offer Shares in Hong Kong Public
Offering (as adjusted after reallocation)
16,027,200 H Shares
Number of Offer Shares in International Offering
(taking into account the full exercise of the Offer Size
Adjustment Option and as adjusted after reallocation)
20,835,300 H Shares
Number of issued Shares upon Listing (before
any exercise of the Over-allotment Option)
193,362,500 Shares
The number of Offer Shares above is determined after taking into account the additional H
Shares issued under the following Offer Size Adjustment Option.
Offer Size Adjustment Option (Upsize Option)
Number of additional Shares issued under the option 4,808,100 H Shares
– Hong Kong Public Offering N/A
– International Offering 4,808,100 H Shares
The Offer Size Adjustment Option has been fully exercised by the Overall Coordinators, pursuant
to which the Company is issuing and allotting 4,808,100 additional H Shares, representing
approximately 15% of the total number of Offer Shares initially available under the Global
Offering, at the Final Offer Price.


--- page 4 ---
– 4 –
Over-allocation
No. of Offer Shares over-allocated (taking into account
the full exercise of the Offer Size Adjustment Option)
12,821,700 H Shares
– International Offering 12,821,700 H Shares
Such over-allocation may be covered by exercising the Over-allotment Option or by making
purchases in the secondary market at prices that do not exceed the Offer Price or through
deferred delivery or a combination of these means. In the event the Over-allotment Option is
exercised, an announcement will be made on the Stock Exchange’s website.
Proceeds
Gross proceeds (Note) HK$1,290.2 million
Less: Est imated listing expenses payable based
on Final Offer Price
HK$(110.8) million
Net proceeds HK$1,179.3 million
Note: Gross proceeds refers to the amount to which the issuer is entitled to receive, taking into account the
full exercise of the Offer Size Adjustment Option, and without taking into account the Over-allotment
Option. For details of the use of proceeds, please refer to the section headed “Future Plans and Use
of Proceeds” of the Prospectus. In the event that the Over-allotment Option is exercised, the Company
will adjust the allocation of the net proceeds on a pro rata basis. During the Track Record Period, the
listing expenses of HK$23.0 million has been charged to the consolidated statements of profit or loss
of the Company.
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 323,706
No. of successful applications 73,406
Subscription level 3,494.78 times
Claw-back triggered Yes
No. of Offer Shares initially available under the Hong Kong
Public Offering
3,205,500
No. of Offer Shares reallocated from the International Offering 12,821,700
Final no. of Offer Shares under the Hong Kong Public Offering 16,027,200
% of final no. of Offer Shares under the Hong Kong Public
Offering to the Global Offering
43.48%
Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can
refer to www.eipo.com.hk/eIPOAllotment  to perform a search by identification number or
www.eipo.com.hk/eIPOAllotment  for the full list of allottees.


--- page 5 ---
– 5 –
INTERNATIONAL OFFERING
No. of placees 141
Subscription Level 40.78 times
No. of Offer Shares initially available under the International
Offering
28,848,900
No. of Offer Shares reallocated to the Hong Kong Public Offering 12,821,700
Final no. of Offer Shares under the International Offering
(taking into account the full exercise of the Offer Size
Adjustment Option, as adjusted after reallocation and subject to
the Over-allotment Option)
20,835,300
% of final no. of Offer Shares under the International Offering to
the Global Offering
56.52%
The Directors confirm that, to the best of their knowledge, information and belief, save for
(a) a waiver from strict compliance with Rule 10.04 of the Listing Rules and written consents
under paragraph 5(2) of Appendix F1 to the Listing Rules (the “ Placing Guidelines ”)
granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in
the International Offering to an existing shareholder and certain close associates of existing
shareholders, and (b) consents under paragraph 5(1) of the Placing Guidelines and Chapter
4.15 of the Guide for New  Listing Applicants in relation to allocations to connected clients
granted by the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and
the public have been financed directly or indirectly by the Company, any of the Directors, the
Supervisors, chief executive of the Company, AIC Parties, substantial Shareholders, existing
Shareholders of the Company or any of its  subsidiaries or their respective close associates;
and (ii) none of the placees and the public who have purchased the Offer Shares are
accustomed to taking instructions from  the Company, any of the Directors, the Supervisors,
chief executive of the Company, AIC Parties, substantial Shareholders, existing Shareholders
of the Company or any of its subsidiaries or their respective close associates in relation to the
acquisition, disposal, voting or other  disposition of Shares registered in his/her/its name or
otherwise held by him/her/it.
1 For details, please see “Others/Additional information” in this announcement.


--- page 6 ---
– 6 –
The placees in the International Offering include the following:
Cornerstone Investors
Investor Note 1
No. of Offer
Shares
allocated
% of Offer
Shares Note 2
% of total
issued Shares
after the
Global
Offering Note 2
Existing
shareholders
or their close
associates
Loyal Valley Capital Advantage
Fund III LP (“ Loyal Valley
Fund III ”)
1,121,300 3.04% 0.58% Yes
Golden Valley Global Limited 897,100 2.43% 0.46% Yes
Golden Valley Value Select
Master Fund (together with Loyal
Valley Fund III and Golden
Valley Global Limited, the “ LVC
Entities ”)
897,100 2.43% 0.46% Yes
Shanghai Gaoyi Asset
Management Partnership
(Limited Partnership) ( ɪऎ৷
ᆇ༟ପ၍ଣΥྫΆุ Ϟ
Υྫ ) (“Shanghai Gaoyi ”)
and Huatai Capital Investment
Limited (“ HTCI”) (in connection
with Huatai Back-to-back TRS
and Huatai Client TRS)
1,794,200 4.87% 0.93% No
Perseverance Asset Management
International (Singapore)
Pte. Ltd.
448,500 1.22% 0.23% No
TruMed Healthcare Master Fund 123,300 0.33% 0.06% No
TruMed Health Innovation Fund
LP
2,119,400 5.75% 1.10% No
OrbiMed Genesis Master Fund,
L.P.
1,401,700 3.80% 0.72% No
The Biotech Growth Trust PLC 841,000 2.28% 0.43% No


--- page 7 ---
– 7 –
Investor Note 1
No. of Offer
Shares
allocated
% of Offer
Shares Note 2
% of total
issued Shares
after the
Global
Offering Note 2
Existing
shareholders
or their close
associates
Huang River Investment Limited 1,794,200 4.87% 0.93% No
E Fund Management Co., Ltd.
(ʮ̡ )
1,379,300 3.74% 0.71% No
E Fund Management (Hong
Kong) Co., Ltd.
(ಥ
ʮ̡ )
190,600 0.52% 0.10% No
FORESIGHT GLOBAL
SUPERIOR CHOICE SPC –
GLOBAL SUPERIOR CHOICE
FUND 1 SP (“ Foresight Funds
GSC Fund 1 ”) and Foresight
Global Superior Choice SPC –
Vision Fund 1 SP (“ Vision
Fund 1 ”)
1,121,300 3.05% 0.58% No
Sage Partners Master Fund 897,100 2.43% 0.46% No
Hankang Biotech Fund III, L.P. 224,200 0.61% 0.12% Yes
Splendid Biotech Fund L.P. 224,200 0.61% 0.12% Yes
Total 15,474,500 41.98% 8.00%
Notes:
1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone
Investors” in the Prospectus.
2. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.
Allotee with Waiver/Consents Obtained
Investor
No. of Offer
Shares
allocated
% of Offer
Shares Note 1
% of total
issued Shares
after the
Global
Offering Note 1 Relationship
Allotee with waiver from strict compliance with Rule 10.04 of the Listing Rules and consent under
paragraph 5(2) of the Placing Guidelines in relation to subscription for Offer Shares by an existing
shareholder
Note 2
Loyal Valley Fund III 1,121,300 3.04% 0.58% Loyal Valley Fund III is
an existing shareholder
of the Company.


--- page 8 ---
– 8 –
Investor
No. of Offer
Shares
allocated
% of Offer
Shares Note 1
% of total
issued Shares
after the
Global
Offering Note 1 Relationship
Allotee with consent under paragraph 5(2) of the Placing Guidelines in relation to subscription for
Offer Shares by close associates of existing Shareholders Note 2
Golden Valley Global
Limited
897,100 2.43% 0.464% Golden Valley Global
Limited is a close
associate of an existing
shareholder of the
Company.
Golden Valley Value
Select Master Fund
897,100 2.43% 0.464% Golden Valley is a
close associate of an
existing shareholder of
the Company.
Splendid Biotech Fund
L.P.
224,200 0.61% 0.116% Splendid Biotech
Fund L.P. is a close
associate of an existing
shareholder of the
Company.
Hankang Biotech Fund
III, L.P. (together with
Splendid Biotech Fund
L.P., the “ Hankang
Entities ”)
224,200 0.61% 0.116% Hankang Biotech Fund
III, L.P. is a close
associate of an existing
shareholder of the
Company.
Bosera Asset
Management
(International) Co.,
Limited (“ Bosera
International ”)
40,000
0.11% 0.02% Bosera International is
a close associate of an
existing shareholder of
the Company.


--- page 9 ---
– 9 –
Investor
No. of Offer
Shares
allocated
% of Offer
Shares Note 1
% of total
issued Shares
after the
Global
Offering Note 1 Relationship
Allotees with consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the
Guide for New Listing Applicants in relation to allocations to connected client Note 3
CITIC Securities
International Capital
Management Limited
(“CSI”)
1,116,600 3.03% 0.58% Connected client as a
placee
China Asset
Management (Hong
Kong) Limited
(“China AM HK ”)
60,000 0.16% 0.03% Connected client as a
placee
UBS Asset
Management
(Singapore) Limited
(“UBS AM ”)
494,000 1.34% 0.26% Connected client as a
placee
Notes:
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.
2. The Company has applied for, and the Stock Exchange has granted, (i) a waiver from strict compliance
with Rule 10.04 of the Listing Rules and a written consent under Paragraph 5(2) of the Placing
Guidelines in relation to allocation to Loyal Valley Fund III, an existing shareholder of Company,
and (ii) a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation
to the LVC Entities, Hankang Entities and Bosera International, each a close associate of existing
Shareholders of the Company, to permit the Company to allocate such Offer Shares in the International
Offering to them and Bosera International. The allocation of Offer Shares to the aforementioned
entities and Bosera International is in compliance with all the conditions under the consent granted by
the Stock Exchange. For details, please refer to the section headed “Others/Additional Information” in
this announcement below.
3. For details of the consent under paragraph 5(1) of the Placing Guidelines and Chapter 4.15 of the Guide for
New Listing Applicants in relation to allocations to connected clients, please refer to the section headed “Others/
Additional Information — Allocation of Offer Shares to connected clients with prior written consent under
paragraph 5(1) of the Placing Guidelines” in this announcement.


--- page 10 ---
– 10 –
LOCK-UP UNDERTAKINGS
AIC Parties
Name
Number of
Shares held in
the Company
subject to lock-up
undertakings
upon Listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon Listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Dr. Kang Xiaoqiang
(“Dr. Kang ”)
Notes 2, 3
7,874,617
(including
3,937,309
H Shares)
2.66% 4.07% July 24, 2026 Note 4
Dr. Lai Shoupeng
(“Dr. Lai ”)Notes 2, 3
6,384,821
(including
3,192,411
H Shares)
2.16% 3.30% July 24, 2026 Note 4
Nanjing Lizhi
Management &
Consulting Center
(Limited Partnership)
(ԯᓿЇΆุ၍ଣ
ፔ༔ʕː
Υྫ ) (“Lizhi
Partnership ”)
Notes 2, 3
12,845,442
(including
6,422,721
H Shares)
4.35% 6.64% July 24, 2026 Note 4
LeadsTech Limited Notes 2, 3 1,920,004
(including
960,002
H Shares)
0.65% 0.99% July 24, 2026 Note 4
LeadsBio Limited Notes 2, 3 1,663,936
(including
1,200,000
H Shares)
0.81% 0.86% July 24, 2026 Note 4
Total 30,688,820 10.63% 15.87%
Notes:
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.
2. Dr. Kang is executive Director and Chief Executive Officer and general manager of the Company. Dr.
Lai is executive Director, Chief Strategic Officer and executive vice president of the Company. Each
of Lizhi Partnership, LeadsBio Limited and LeadsTech Limited is a share incentive platform of the
Company. Please refer to the section headed “Substantial Shareholders” of the Prospectus for more
information.
Immediately before completion of the Global Offering, Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio
Limited and LeadsTech Limited were entitled to exercise voting rights of approximately 19.61% of
the Company in aggregate pursuant to a concert party agreement entered into among the parties.
Immediately following the completion of the Global Offering, Dr. Kang, Dr. Lai, Lizhi Partnership,
LeadsBio Limited and LeadsTech Limited will together control the voting rights of approximately
15.87% of the total issued share capital of our Company. Accordingly, Dr. Kang, Dr. Lai, Lizhi
Partnership, LeadsBio Limited and LeadsTech Limited are a group of AIC Parties and each of them is
subject to the same lock-up as disclosed above.


--- page 11 ---
– 11 –
3. In view of the concert party agreement, each of Dr. Kang, Dr. Lai, Lizhi Partnership, LeadsBio Limited
and LeadsTech Limited is deemed to be interested in the interest of each other under the SFO.
4. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws.
In accordance with the relevant Listing Rules/guidance materials, the required lock-up for existing
Shareholders ends on July 24, 2026, being 12 months following the Listing Date.
Cornerstone Investors
Name
Number of
H Shares held
in the Company
subject to
lock-up
undertakings
upon Listing
% of
total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon Listing Note 1
% of
shareholding in
the Company
subject to
lock-up
undertakings
upon Listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Loyal Valley Fund III 1,121,300 0.76% 0.58% January 24, 2026
Golden Valley Global
Limited
897,100 0.61% 0.46% January 24, 2026
Golden Valley Value
Select Master Fund
897,100 0.61% 0.46% January 24, 2026
Shanghai Gaoyi and
HTCI (in connection with
Huatai Back-to-back TRS
and Huatai Client TRS)
1,794,200 1.21% 0.93% January 24, 2026
Perseverance
Asset Management
International (Singapore)
Pte. Ltd.
448,500 0.30% 0.23% January 24, 2026
TruMed Healthcare
Master Fund
123,300 0.08% 0.06% January 24, 2026


--- page 12 ---
– 12 –
Name
Number of
H Shares held
in the Company
subject to
lock-up
undertakings
upon Listing
% of
total issued
H Shares after
the Global
Offering subject
to lock-up
undertakings
upon Listing Note 1
% of
shareholding in
the Company
subject to
lock-up
undertakings
upon Listing Note 1
Last day subject
to the lock-up
undertakings Note 2
TruMed Health
Innovation Fund LP
2,119,400 1.43% 1.10% January 24, 2026
OrbiMed Genesis Master
Fund, L.P.
1,401,700 0.95% 0.72% January 24, 2026
The Biotech Growth
Trust PLC
841,000 0.57% 0.43% January 24, 2026
Huang River Investment
Limited
1,794,200 1.21% 0.93% January 24, 2026
E Fund Management Co.,
Ltd. (၍ଣ
ʮ̡ )
1,379,300 0.93% 0.71% January 24, 2026
E Fund Management
(Hong Kong) Co., Ltd.
(˙༺༟ପ၍ଣ
ʮ̡ )
190,600 0.13% 0.10% January 24, 2026
Foresight Funds GSC
Fund 1
437,300 0.30% 0.23% January 24, 2026
Vision Fund 1 684,000 0.46% 0.35% January 24, 2026
Sage Partners Master
Fund
897,100 0.61% 0.46% January 24, 2026
Hankang Biotech Fund
III, L.P.
224,200 0.15% 0.12% January 24, 2026
Splendid Biotech Fund
L.P.
224,200 0.15% 0.12% January 24, 2026
Total 15,474,500 10.47% 8.00%
Notes:
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.
2. In accordance with the relevant cornerstone investment agreements, the required lock-up ends
on January 24, 2026. The Cornerstone Investors will cease to be prohibited from disposing of or
transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after
the indicated date.


--- page 13 ---
– 13 –
Pre-IPO Investors (as defined in the “History, Development and Corporate Structure”
section of the Prospectus)
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Nanjing Ennovation Raylight
Healthcare Investment
Partnership (Limited
Partnership) (್๿
Έ਄ੰପุҳ༟ΥྫΆุ
Υྫ )
Note 3
5,901,290
(including
2,950,645
H Shares)
2.00% 3.05% July 24, 2026
Nanjing Jieyuan Growth
Venture Capital Partnership
(Limited Partnership) (ԯ
௴ุҳ༟ΥྫΆ
Υྫ )
Note 3
2,974,369
(including
2,974,369
H Shares)
2.01% 1.54% July 24, 2026
Nanjing Enjie Venture
Capital Partnership (Limited
Partnership)
(ઠ௴ุҳ༟Υྫ
Υྫ )
Note 3
1,332,237
(including
666,119
H Shares)
0.45% 0.69% July 24, 2026
Nanjing Ennovation Chengfeng
Entrepreneurship Investment
Partnership (Limited
Partnership) (್яᔮ
Υ
ྫ)
Note 3
937,500 – 0.48% July 24, 2026
Nanjing Jiakang Ruizhen
Venture Investment Partnership
(Limited Partnership) (ԯ
Գੰ๿ጲ௴ุҳ༟Υྫ
Υྫ )
Note 3
684,016 – 0.35% July 24, 2026
Suzhou Jianxin Hankang
Venture Investment Partnership
Enterprise
(Limited Partnership)
(ဏੰ௴ุҳ༟
Υྫ )
(“Suzhou Hankang ”)
Note 4
6,853,584
(including
6,853,584
H Shares)
4.64% 3.54% July 24, 2026


--- page 14 ---
– 14 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Beijing Hankang Jianxin
Venture Investment Co., Ltd.
(௴ุҳ༟
ʮ̡ ) (“Beijing
Hankang ”)
Note 4
3,036,869
(including
3,036,869
H Shares)
2.06% 1.57% July 24, 2026
Hankang Small and Medium
Enterprises Development
Fund (Weifang) Partnership
Enterprise (Limited
Partnership) ( ဏੰʕʃΆุ
ᐂ ѥΥྫΆุ
Υྫ ) (“Hankang
SME”)
Note 4
2,682,372
(including
999,178
H Shares)
0.68% 1.39% July 24, 2026
Loyal Valley Fund III Note 5 9,991,770 – 5.17% July 24, 2026
Shanghai Leyong Investment
Partnership Enterprise (Limited
Partnership) ( ɪऎᆀ͑ҳ
Υྫ )
(“Shanghai Leyong ”)
Note 5
1,998,356 – 1.03% July 24, 2026
Shanghai Jishi Lemei Private
Equity Investment Fund
Partnership Enterprise
(Limited Partnership)
(ӷ෍ҳ༟
Υྫ )
(“Shanghai Jishi Lemei”)
Note 5
1,579,970
(including
895,954
H Shares)
0.61% 0.82% July 24, 2026
Beijing Chongshan Yuanwei
Investment Center (Limited
Partnership) (މ
Υྫ )
3,261,914
(including
3,261,914
H Shares)
2.21% 1.69% July 24, 2026
Ningbo Huaige Gongxin
Venture Investment
Partnership Enterprise
(Limited Partnership)
(௴ุҳ༟Υ
Υྫ )
Note 6
4,611,383
(including
4,611,383
H Shares)
3.12% 2.38% July 24, 2026


--- page 15 ---
– 15 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Jingning Huaige Ruixin
Venture Investment Partnership
Enterprise (Limited
Partnership) (ڦ
௴ุҳ༟ΥྫΆุ
Υྫ )
Note 6
1,665,296
(including
832,648
H Shares)
0.56% 0.86% July 24, 2026
Chengdu Huaige Guosheng
Venture Investment Partnership
(Limited Partnership) ( ϓேᕿ
਷͛௴ุҳ༟ΥྫΆุ
Υྫ )
Note 6
684,016 – 0.35% July 24, 2026
New Hope Medical Health
Nanjing Investment Center
(Limited Partnership)
(ԯҳ༟
Υྫ )
5,662,889
(including
5,662,889
H Shares)
3.83% 2.93% July 24, 2026
Kunming High-tech Nuotai
Big Health Industry Investment
Partnership Enterprise (Limited
Partnership) (৷อፕइ
ɽ਄ੰପุҳ༟ΥྫΆุ
Υྫ )
Note 7
3,469,379
(including
3,469,379
H Shares)
2.35% 1.79% July 24, 2026
Wuhan Hofon Jianmin Yichao
Investment Partnership
Enterprise (Limited
Partnership) (ဏശ˙
਄͏ᔼᆓҳ༟ΥྫΆุ
Υྫ )
Note 7
325,557
(including
325,557
H Shares)
0.22% 0.17% July 24, 2026
Hangzhou Hofon Heyi
Investment Management
Partnership Enterprise (Limited
Partnership)
(ψശ˙ձ᎚ҳ༟၍ଣΥ
Υྫ )
Note 7
867,343
(including
867,343
H Shares)
0.59% 0.45% July 24, 2026
Nanjing Jiangbei Medical
Innovation Industry Fund
(Limited Partnership)
(ԯϪ̏ᔼᐕ௴อପุ
Υྫ )
Note 8
4,817,264
(including
4,817,264
H Shares)
3.26% 2.49% July 24, 2026


--- page 16 ---
– 16 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Nanjing Jiangbei High-tech
Industrial Development Equity
Investment Fund (Limited
Partnership) (ԯϪ̏৷อ
ᛆҳ༟ਿ
Υྫ )
Note 8
1,221,511 – 0.63% July 24, 2026
Nanjing Qiruiyoukang Venture
Capital Partnership (Limited
Partnership) (ԯՉ๿Сੰ
ࠢ
Υྫ )
Note 8
3,053,782
(including
1,526,891
H Shares)
1.03% 1.58% July 24, 2026
Hangzhou Yuhang Longpan
Health Medical Equity
Investment Fund Partnership
Enterprise (Limited
Partnership) (Ꮂᇂ
Υ
Υྫ )
4,662,821
(including
4,662,821
H Shares)
3.16% 2.41% July 24, 2026
Shanghai Zhuangzhong
Venture Investment Co., Ltd.
( ɪऎ୿ᒤ௴ุҳ༟
ʮ̡ )
3,941,250
(including
3,941,250
H Shares)
2.67% 2.04% July 24, 2026
Shanghai Guohong Zhiyan
Venture Investment
Partnership Enterprise (Limited
Partnership) ( ɪऎ਷ᒿ
౽Ԋ௴ุҳ༟ΥྫΆุ
Υྫ )
3,664,534
(including
3,664,534
H Shares)
2.48% 1.90% July 24, 2026
Shenzhen Capital Group Co.,
Ltd. ( ଉέ̹௴อҳ༟ණྠ
ʮ̡ )
Note 9
1,665,296
(including
832,648
H Shares)
0.56% 0.86% July 24, 2026
Shenzhen Hongtu Medical
Health Industry Equity
Investment Fund Partnership
(L.P.) (ɺᔼᐕ਄ੰ
ΥྫΆ
Υྫ )
Note 9
1,665,296
(including
832,648
H Shares)
0.56% 0.86% July 24, 2026
Xiamen Dyee Evergreen
Venture Investment
Partnership Enterprise
(Limited Partnership) (ᅃ
௴ุҳ༟ΥྫΆุ
Υྫ )
3,330,584
(including
3,330,584
H Shares)
2.25% 1.72% July 24, 2026


--- page 17 ---
– 17 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Xinyu City Shangrun
Investment Partnership
Enterprise (Limited
Partnership) ( อЯ̹ɪᆗҳ
Υྫ )
Note 10
1,832,271
(including
1,832,271
H Shares)
1.24% 0.95% July 24, 2026
Xinyu City Xinguolu
Investment Partnership
Enterprise (Limited
Partnership) ( อЯ̹อ਷༩
ࠢ
Υྫ )
Note 10
666,110
(including
666,110
H Shares)
0.45% 0.34% July 24, 2026
Xinyu Shangxuan Equity
Investment Partnership
(Limited Partnership) ( อЯ
ᛆҳ༟ΥྫΆุ
Υྫ )
Note 10
500,000 – 0.26% July 24, 2026
Anhui Kunlu Venture
Capital Partnership (Limited
Partnership) (༩௴ุ
ҳ༟ΥྫΆุ
Υྫ )
Note 10
1,350,000 – 0.70% July 24, 2026
Nanjing Kaitai Venture
Investment Partnership
Enterprise (Limited
Partnership) (ԯ௱इ௴ุ
Υྫ )
774,579
(including
774,579
H Shares)
0.52% 0.40% July 24, 2026
Gongqingcheng Jiuyou
Shenghui Investment
Management Partnership
Enterprise (Limited
Partnership) (ɮʾ͛
ฯҳ༟၍ଣΥྫΆุ
Υྫ )
Note 11
1,258,157
(including
1,258,157
H Shares)
0.85% 0.65% July 24, 2026
Gongqingcheng Jiuyou
Shengrui Investment
Management Partnership
Enterprise (Limited
Partnership) (ɮʾ
͛๿ҳ༟၍ଣΥྫΆุ
Υྫ )
Note 11
1,184,865
(including
1,184,865
H Shares)
0.80% 0.61% July 24, 2026


--- page 18 ---
– 18 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
KPC Pharmaceuticals, Inc.
(ʮ̡ )
2,443,022
(including
2,443,022
H Shares)
1.65% 1.26% July 24, 2026
CCBI Venture Capital
Shenzhen Co., Ltd (ვ਷ყ
ʮ̡ )
2,275,954
(including
2,275,954
H Shares)
1.54% 1.18% July 24, 2026
AJS Alphatech Limited 2,131,578
(including
2,131,578
H Shares)
1.44% 1.10% July 24, 2026
Yellow River Delta Rongchang
(Yantai) Venture Capital
Partnership Enterprise (Limited
Partnership) (࿲
๧ ̨௴ุҳ༟ΥྫΆุ
Υྫ )
1,998,356
(including
1,998,356
H Shares)
1.35% 1.03% July 24, 2026
Jiaxing Minglang No. 2
Equity Investment Fund
Partnership Enterprise (Limited
Partnership) (ɚ໮
ΥྫΆุ
Υྫ )
1,832,271
(including
1,832,271
H Shares)
1.24% 0.95% July 24, 2026
Guangdong Bozi Tongze No. 1
Equity Investment Partnership
(Limited Partnership) ( ᄿ
ᛆҳ
Υྫ )
(“Guangdong Bozi ”)
Note 12
1,665,296
(including
1,665,296
H Shares)
1.13% 0.86% July 24, 2026
Nanjing Jingyong Medical
Health Venture Investment
Fund Partnership Enterprise
(Limited Partnership) (ԯ౻
ږ
Υྫ )
1,589,744
(including
1,589,744
H Shares)
1.08% 0.82% July 24, 2026
Gongqingcheng Ruiji
Phase V Investment
Partnership Enterprise (Limited
Partnership) (๿Λʞ
Υྫ )
1,332,237
(including
1,332,237
H Shares)
0.90% 0.69% July 24, 2026


--- page 19 ---
– 19 –
Name
Number of
shares held in
the Company
subject to lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-up
undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Truman Enterprises (Hong
Kong) limited
1,332,237
(including
1,332,237
H Shares)
0.90% 0.69% July 24, 2026
Jiaxing Tongren Hefu Equity
Investment Partnership
Enterprise (Limited
Partnership) ( ྗጳΝɛ
ᛆҳ༟ΥྫΆุ
Υྫ )
1,332,237
(including
1,332,237
H Shares)
0.90% 0.69% July 24, 2026
Ningbo Lan Hui Investment
Management Partnership
Enterprise (Limited Partnership
(ᜡᅆҳ༟၍ଣΥྫΆ
Υྫ )
1,221,511
(including
610,756
H Shares)
0.41% 0.63% July 24, 2026
Jiaxing Zhongying Zhonghui
Venture Capital Partnership
(Limited Partnership) ( ྗጳʕ
ᙊ଺ි௴ุҳ༟ΥྫΆุ
Υྫ )
1,000,000
(including
1,000,000
H Shares)
0.68% 0.52% July 24, 2026
Liang Jie ( ૑௫ ) 937,500
(including
937,500
H Shares)
0.63% 0.48% July 24, 2026
Sun Yi (᎚ ) 937,500
(including
937,500
H Shares)
0.63% 0.48% July 24, 2026
Guangzhou Kaide Phase I
Biopharmaceutical Industry
Investment Fund Partnership
(Limited Partnership) ( ᄿψ௱
ᔼᖹପุҳ༟
Υྫ )
1,500,000 – 0.78% July 24, 2026
Intellective Biologics (Suzhou)
Limited (ᘽ ψ
ʮ̡ )
1,150,000 – 0.59% July 24, 2026
Total 118,787,873 59.66% 61.43%
Notes:
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.


--- page 20 ---
– 20 –
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
3. Each an investment arm of Ennovation Ventures (್௴ҳ );
4. Each an investment arm of Hankang  Capital. The Company has applied for, and the Stock Exchange
has granted, a written consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation
to Hankang Entities, each a close associate of Suzhou Hankang, Beijing Hankang and Hankang SME,
to permit the Company to allocate such Offer Shares in the International Offering to Hankang Entities.
The allocation of Offer Shares to Hankang Entities is in compliance with all the conditions under
the consent granted by the Stock Exchange. Please refer to the section headed “Waivers from Strict
Compliance with the Listing Rules and Exemption from Strict Compliance with the Companies (Winding
up and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing Shareholder
and Close Associates of Existing Shareholders” in the Prospectus for details.
5. Each an investment arm of Loyal Valley Capital. The Company has applied for, and the Stock Exchange
has granted, (i) a waiver from strict compliance with Rule 10.04 of the Listing Rules and a written
consent under Paragraph 5(2) of the Placing Guidelines in relation to allocation to Loyal Valley
Fund III, an existing shareholder of Company, and (ii) a written consent under Paragraph 5(2) of the
Placing Guidelines in relation to allocation to LVC Entities, each a close associate of Loyal Valley
Fund III, Shanghai Leyong and Shanghai Jishi Lemei, to permit the Company to allocate such Offer
Shares in the International Offering to LVC Entities. The allocation of Offer Shares to LVC Entities is
in compliance with all the conditions under the consent granted by the Stock Exchange. Please refer to
the section headed “Waivers from Strict Compliance with the Listing Rules and Exemption from Strict
Compliance with the Companies (Winding up and Miscellaneous Provisions) Ordinance — Cornerstone
Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders” in the
Prospectus for details.
6. Each an investment arm of Huaige Capital.
7. Each an investment arm of Hofon Capital.
8. Each a limited partnership controlled by Nanjing Jiangbei New Area Management Committee (Nanjing
High-tech Industrial Development Zone Management Committee, Nanjing Area Management Committee
of China (Jiangsu) Pilot Free Trade Zone) (
ԯ৷อҦஔପุක೯
ึ  ).
9. Each ultimately controlled by the State-owned Assets Supervision and Administration Commission of
Shenzhen Municipal People’s Government (ึ ).
10. Each an investment arm of NSR Capital.
11. Both are investment arms of Jiuyou Capital.
12. The Company has applied for, and the Stock Exchange has granted, a written consent under Paragraph
5(2) of the Placing Guidelines in  relation to allocation to Bosera  International, a close  associate of
Guangdong Bozi, to permit the Company to allocate such Offer Shares in the International Offering
to Bosera International as a placee. The allocation of Offer Shares to Bosera International is in
compliance with all the conditions under the consent granted by the Stock Exchange. For details, please
refer to the section headed “Others/Additional Information” in this announcement below.


--- page 21 ---
– 21 –
Existing Shareholders (other than the AIC Parties and the Pre-IPO Investors as defined in
the “History, Development and Corporate Structure” section of the Prospectus)
Name
Number of
shares held in
the Company
subject to
lock-up
undertakings
upon listing
% of
total issued
H Shares after the
Global Offering
subject to lock-up
undertakings
upon Listing Note 1
% of
shareholding
in the Company
subject to lock-
up undertakings
upon listing Note 1
Last day subject
to the lock-up
undertakings Note 2
Lu Dongcheng 7,023,307
(including
7,023,307
H Shares)
4.75% 3.63% July 24, 2026
Total 7,023,307 4.75% 3.63%
Notes:
1. Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
Over-allotment Option.
2. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
PLACEE CONCENTRATION ANALYSIS
Placees*
Number of
H Shares allotted
Allotment as % of
International Offering
(taking into account the
full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment Option)
Allotment as % of
total Offer Shares
(taking into account the
full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment Option)
Number of
Shares held
upon Listing
% of total issued share
capital upon Listing
(taking into account the
full exercise of the Offer
 Size Adjustment
Option and assuming
no exercise of the
Over-allotment Option)
Top 1 2,915,500 13.99% 7.91% 16,485,596 8.53%
Top 5 11,437,800 54.90% 31.03% 25,007,896 12.93%
Top 10 16,847,000 80.86% 45.70% 30,417,096 15.73%
Top 25 22,786,700 109.37% 61.82% 48,929,621 25.30%
Note:
* Ranking of placees is based on the number of H Shares allotted to the placees.


--- page 22 ---
– 22 –
H SHAREHOLDER CONCENTRATION ANALYSIS
H Shareholders*
Number of
 H Shares
allotted
Allotment as % of
International Offering
(taking into account
the full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Allotment as % of
total Offer Shares
(taking into account
the full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Number of
H Shares held
upon Listing
% of total issued H
Shares capital upon
Listing (taking
into account the full
exercise of the Offer
Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Number of
Shares held
upon Listing
Top 1 0 0.00% 0.00% 15,712,443 10.63% 30,688,820
Top 5 488,400 2.34% 1.32% 47,049,069 31.84% 71,695,321
Top 10 528,400 2.54% 1.43% 71,462,339 48.37% 97,625,255
Top 25 11,966,200 57.43% 32.46% 111,341,005 75.36% 152,028,063
Notes:
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
** Including H Shares allotted under the Hong Kong Public Offering and International Offering and among
which, 16,027,200 H Shares were allotted under the Hong Kong Public Offering and 20,835,300 H Shares
were allotted under the International Offering.
SHAREHOLDER CONCENTRATION ANALYSIS
Shareholders*
Number of
H Shares
allotted
Allotment as % of
International Offering
(taking into account
the full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Allotment as % of
total Offer Shares
(taking into account
the full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Number of
H Shares held
 upon Listing
Number of
Shares held
upon Listing
% of total issued share
capital upon Listing
(taking into account
the full exercise of the
Offer Size Adjustment
Option and assuming
no exercise of the
Over-allotment
Option)
Top 1 0 0.00% 0.00% 15,712,443 30,688,820 15.87%
Top 5 3,403,900 16.34% 9.23% 43,837,216 81,157,610 41.97%
Top 10 3,403,900 16.34% 9.23% 71,292,543 110,129,601 56.95%
Top 25 10,172,000 48.82% 27.59% 111,212,101 153,564,455 79.42%
Notes:
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon
Listing.
** Including H Shares allotted under the Hong Kong Public Offering and International Offering and amongst
which, 16,027,200 H Shares were allotted under the Hong Kong Public Offering and 20,835,300 H Shares
were allotted under the International Offering.


--- page 23 ---
– 23 –
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, a total of 323,706 valid
applications made by the public will be conditionally allocated on the basis set out below:
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS
BASIS OF
ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED
OF THE TOTAL
NO. OF
SHARES
APPLIED FOR
POOL A
100 53,525 145 out of 53,525 to receive 100 Shares 0.27%
200 19,712 107 out of 19,712 to receive 100 Shares 0.27%
300 11,698 95 out of 11,698 to receive 100 Shares 0.27%
400 6,756 73 out of 6,756 to receive 100 Shares 0.27%
500 18,137 246 out of 18,137 to receive 100 Shares 0.27%
600 5,993 97 out of 5,993 to receive 100 Shares 0.27%
700 4,455 84 out of 4,455 to receive 100 Shares 0.27%
800 5,314 115 out of 5,314 to receive 100 Shares 0.27%
900 3,486 85 out of 3,486 to receive 100 Shares 0.27%
1,000 31,166 844 out of 31,166 to receive 100 Shares 0.27%
1,500 14,390 584 out of 14,390 to receive 100 Shares 0.27%
2,000 12,793 693 out of 12,793 to receive 100 Shares 0.27%
2,500 10,507 711 out of 10,507 to receive 100 Shares 0.27%
3,000 7,052 573 out of 7,052 to receive 100 Shares 0.27%
3,500 5,694 540 out of 5,694 to receive 100 Shares 0.27%
4,000 3,445 373 out of 3,445 to receive 100 Shares 0.27%
4,500 2,473 301 out of 2,473 to receive 100 Shares 0.27%
5,000 6,618 896 out of 6,618 to receive 100 Shares 0.27%
6,000 5,206 846 out of 5,206 to receive 100 Shares 0.27%
7,000 3,752 711 out of 3,752 to receive 100 Shares 0.27%
8,000 4,042 875 out of 4,042 to receive 100 Shares 0.27%
9,000 2,911 709 out of 2,911 to receive 100 Shares 0.27%
10,000 19,734 5,343 out of 19,734 to receive 100 Shares 0.27%
20,000 11,299 6,118 out of 11,299 to receive 100 Shares 0.27%
30,000 6,956 5,650 out of 6,956 to receive 100 Shares 0.27%
40,000 4,144 100 Shares plus 344 out of  4,144 to receive
additional 100 Shares
0.27%
50,000 3,592 100 Shares plus 1,270 out of  3,592 to receive
additional 100 Shares
0.27%
60,000 2,632 100 Shares plus 1,643 out of  2,632 to receive
additional 100 Shares
0.27%
70,000 2,055 100 Shares plus 1,840 out of  2,055 to receive
additional 100 Shares
0.27%
80,000 1,933 200 Shares plus 321 out of  1,933 to receive
additional 100 Shares
0.27%
90,000 1,505 200 Shares plus 657 out of  1,505 to receive
additional 100 Shares
0.27%
100,000 10,323 200 Shares plus 7,302 out of  10,323 to receive
additional 100 Shares
0.27%

303,298 Total number of Pool A successful applicants:
52,998


--- page 24 ---
– 24 –
NO. OF SHARES
APPLIED FOR
NO. OF VALID
APPLICATIONS
BASIS OF
ALLOTMENT/BALLOT
APPROXIMATE
PERCENTAGE
ALLOTTED
OF THE TOTAL
NO. OF
SHARES
APPLIED FOR
POOL B
200,000 10,608 100 Shares plus 10,019 out of  10,608 to receive
additional 100 Shares
0.10%
300,000 3,411 200 Shares plus 3,127 out of  3,411 to receive
additional 100 Shares
0.10%
400,000 1,577 300 Shares plus 1,402 out of  1,577 to receive
additional 100 Shares
0.10%
500,000 1,103 400 Shares plus 950 out of  1,103 to receive
additional 100 Shares
0.10%
600,000 649 500 Shares plus 541 out of  649 to receive
additional 100 Shares
0.10%
700,000 478 600 Shares plus 385 out of  478 to receive
additional 100 Shares
0.10%
800,000 360 700 Shares plus 280 out of  360 to receive
additional 100 Shares
0.10%
900,000 275 800 Shares plus 206 out of  275 to receive
additional 100 Shares
0.10%
1,000,000 741 900 Shares plus 535 out of  741 to receive
additional 100 Shares
0.10%
1,500,000 175 1,400 Shares plus 102 out of  175 to receive
additional 100 Shares
0.10%
1,602,700 1,031 1,500 Shares plus 599 out of  1,031 to receive
additional 100 Shares
0.10%

20,408 Total number of Pool B successful applicants:
20,408
As of the date of this announcement, the relevant subscription monies previously deposited
in the designated nominee accounts have been remitted back to the accounts of all HKSCC
participants. Investors should contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in
respect of which consent has been obtained, the Company has complied with the Listing Rules
and guidance materials in relation to the placing, allotment and listing of the Company’s H
Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by
the placees or the public (as the case may be) directly or indirectly for each Offer Share
subscribed for or purchased by them was the same as the final Offer Price in addition to any
brokerage, AFRC transaction levy, SFC transaction levy and Hong Kong Stock Exchange
trading fee payable.


--- page 25 ---
– 25 –
OTHERS/ADDITIONAL INFORMATION
Reallocation and Offer Size Adjustment Option
As the Hong Kong Public Offering has been over-subscribed by more than 100 times of the
number of the Offer Shares initially available for subscription under the Hong Kong Public
Offering, the reallocation procedure as disclosed in the paragraph headed “Structure of the
Global Offering — The Hong Kong Public Offering — Reallocation and Clawback” in the
Prospectus has been applied.
The Offer Size Adjustment Option has been fully exercised, pursuant to which the
Company is issuing and allotting 4,808,100 additional H Shares, representing 15% of
the total number of Offer Shares initially available under the Global Offering, at the
Final Offer Price. All of the additional H Shares that would be allotted and issued by
the Company pursuant to the full exercise of the Offer Size Adjustment Option will be
allocated to the International Offering. Accordingly, the total number of Offer Shares
finally available under the Global Offering (taking into account the full exercise of the
Offer Size Adjustment Option and before any exercise of the Over-allotment Option) that
would be allotted and issued by the Company is 36,862,500 H Shares and the total issued
share capital of the Company upon Listing (taking into account the full exercise of the
Offer Size Adjustment Option and before any exercise of the Over-allotment Option) will
be 193,362,500 Shares.
As a result of the above, the final number of Offer Shares under the Hong Kong Public
Offering is adjusted to 16,027,200 H Shares, representing approximately 43.48% of Offer
Shares initially available under the Global Offering (assuming the Over-allotment Option
is not exercised), and the final number of Offer Shares under the International Offering is
adjusted to 20,835,300 Shares, representing 56.52% of the total number of Offer Shares
under the Global Offering (assuming the Over-allotment Option is not exercised).
Allocation of Offer Shares to an existing shareholder as placee (with waiver from
strict compliance with Rule 10.04 of the Listing Rules and a written consent
under paragraph 5(2) of the Placing Guidelines) and to close associates of existing
Shareholders as placees (with prior written consent under Paragraph 5(2) of the
Placing Guidelines)
Loyal Valley Fund III
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted,
a waiver from strict compliance with Rule 10.04 of the Listing Rules to permit the
Company to allocate such Offer Shares in the International Offering to Loyal Valley Fund
III, an existing shareholder of Company. Please refer to the section headed “Waivers from
Strict Compliance with the Listing Rules and Exemptions from Strict Compliance with
the Companies (Winding Up and Miscellaneous Provisions) Ordinance — Cornerstone
Subscriptions by an Existing Shareholder and Close Associates of Existing Shareholders”
in the Prospectus for details.


--- page 26 ---
– 26 –
LVC Entities and Hankang Entities
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted,
a written consent under paragraph 5(2) of the Placing Guidelines to permit the Company
to allocate such Offer Shares in the International Offering to  LVC Entities and Hankang
Entities. Please refer to the section headed “Waivers from Strict Compliance with the
Listing Rules and Exemptions from Strict Compliance with the Companies (Winding Up
and Miscellaneous Provisions) Ordinance — Cornerstone Subscriptions by an Existing
Shareholder and Close Associates of Existing Shareholders” in the Prospectus for details.
Bosera International
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted,
a consent under paragraph 5(2) of the Placing Guidelines to permit the Company to
allocate such Offer Shares in the International Offering to Bosera International. Bosera
International is a close associate of Guangdong Bozi, an existing Shareholder of the
Company. The allocation of Offer Shares to Bosera International is in compliance with all
the conditions under the consent granted by the Stock Exchange, including but not limited
to (i) the Company will comply with the public float requirements under rule 8.08(1) and
18A.07, and (ii) no preferential treatment in allocation was given to Bosera International.
Allocation of Offer Shares to connected clients with prior written consent under
paragraph 5(1) of the Placing Guidelines
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted,
a consent under paragrap h 5(1) of the Plac ing Guidelines to permit  certain Offer Shares
to be placed to connected clients of their connected distributors under the International
Offering pursuant to the Placing Guidelines. Details of the placement to connected clients
are set out below:


--- page 27 ---
– 27 –
No.
Connected
Distributor
Connected
Client/Placee
Relationship
with the
Connected
Distributor
Information of
the Connected
Client
Whether the
Connected
Client will hold
the beneficial
interest of the
Offer Shares on a
non-discretionary
basis or
discretionary
basis for
independent third
parties
Number of
Shares to be
subscribed
Approximate
% to the Offer
Shares under
the Global
Offering (taking
into account the
full exercise of
the Offer Size
Adjustment
Option and
assuming no
exercise of the
Over-allotment
Option)
Approximate
% to the
total issued
share capital
immediately
following
completion
of the Global
Offering (taking
into account the
full exercise of
the Offer Size
Adjustment
Option and
assuming no
exercise of the
Over-allotment
Option)
1. CLSA Limited
(“CLSA”)
CSI CSI is a member
of the same
group of
companies as
CLSA.
Please refer to
Note 1
Non-discretionary
basis for
independent
third parties
1,116,600 3.03% 0.58%
2. CLSA China AM HK China AM HK
is a member
of the same
group of
companies as
CLSA
Please refer to
Note 2
Discretionary basis
for independent
third parties
60,000 0.16% 0.03%
3. UBS AG Hong
Kong Branch
Wealth
Management
(“UBS WM ”)
UBS AM UBS AM is a
member of the
same group of
companies as
UBS WM
Please refer to
Note 3
Discretionary basis
for independent
third parties
494,000 1.34% 0.26%


--- page 28 ---
– 28 –
1. CSI will act as the single counterparty of a back-to-back total return swap transaction (the “ CSI
Back-to-back TRS ”) to be entered into by CSI in connection with a total return swap order (the “ CSI
Client TRS ”) placed and fully funded by its ultimate clients (the “ CSI Ultimate Clients ”), by which
CSI will pass the full economic exposure of the Offer Shares placed to CSI to the CSI Ultimate Clients.
CSI will hold the beneficial interest of the Offer Shares on behalf of the CSI Ultimate Clients on a non-
discretionary basis. The CSI Ultimate Clients may exercise their early termination rights to terminate the
CSI Client TRS at any time from the trade date of the CSI Client TRS which should be on or after the date
on which the Offer Shares are listed on the Stock Exchange. Upon the final maturity or termination of the
CSI Client TRS by the CSI Ultimate Clients, CSI will dispose of the Offer Shares on the secondary market
and the CSI Ultimate Clients will receive a final termination amount of the CSI Back-to-back TRS which
will have taken into account all the economic returns or economic loss in relation to the Offer Shares and
the fixed amount of transaction fees of the CSI Back-to-back TRS and the CSI Client TRS. CSI will not
exercise the voting right of the Offer Shares during the terms of the CSI Back-to-back TRS.
To the best knowledge of CSI and after making all reasonable enquiries, each of the CSI Ultimate Clients is
an independent third party of the Company, its subsidiaries and substantial shareholders, CSI, CLSA and
the companies which are members of the same group of CLSA.
2. China AM HK will subscribe for and hold the Offer Shares as a placee under the International Offering
in accounts in its capacity as the discretionary fund manager managing assets on behalf of its underlying
clients. To the best knowledge of China AM HK after due enquiry, each of the underlying clients of China
AM HK is an independent third party of the Company, its subsidiaries, China AM HK and CLSA and the
companies which are members of the same group of CLSA.
3. UBS AM, in the capacity as the investment advisor to and delegate of the investment manager for and on
behalf of certain funds, segregated accounts and/or mandates (“ Underlying Clients ”), will subscribe for
the Offer Shares for and on behalf of its Underlying Clients on discretionary basis.
To the best knowledge of UBS AM, each of its underlying clients is an independent third party of the
Company, its subsidiaries and substantial shareholders, UBS AM and UBS WM and the companies which
are members of the same group of UBS WM.


--- page 29 ---
– 29 –
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited
and Hong Kong Securities Clearing Company Limited take no responsibility for the
contents of this announcement, make no representation as to its accuracy or completeness
and expressly disclaim any liability whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in
or into the United States (including its territories and possessions, any state of the United
States and the District of Columbia). This announcement does not constitute or form
a part of any offer or solicitation to purchase or subscribe for securities in the United
States. The Offer Shares have not been, and will not be, registered under the United States
Securities Act of 1933, as amended (the “ U.S. Securities Act ”). The securities may not be
offered or sold in the United States except pursuant to an exemption from the registration
requirements of the U.S. Securities Act and in compliance with any applicable state
securities laws, or outside the United States unless in compliance with Regulation S under
the U.S. Securities Act. There will be no public offer of securities in the United States.
The Offer Shares are being offered and sold (1) solely to qualified institutional buyers
as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from
registration under the U.S. Securities Act and (2) outside the United States in offshore
transactions in reliance on Regulation S under the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation
or offer to acquire, purchase or subscribe for securities. This announcement is not a
prospectus. Potential investors should read the Prospectus dated July 17, 2025 issued
by Nanjing Leads Biolabs Co., Ltd. for detailed information about the Global Offering
described below before deciding whether or not to invest in the H Shares thereby being
offered.
* Potential investors of the Offer Shares should note that the Overall Coordinators (for
themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate
their obligations under the Hong Kong Underwriting Agreement with immediate effect
upon the occurrence of any of  the events set out in  the section headed “Underwriting —
Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for
Termination” in the Prospectus  at any time prior to 8:00 a.m. (Hong Kong time) on the
Listing Date (which is currently expected to be on Friday, July 25, 2025).


--- page 30 ---
– 30 –
PUBLIC FLOAT
Immediately after the completion of the Global Offering, after taking into account of the
full exercise of the Offer Size Adjustment Option and without taking into account of the
Over-allotment Option, an aggregate of 125,445,815 H Shares, representing approximately
64.88% of the issued share capital of the Company will be held in public hands. Therefore,
the number of H Shares held in public hands represents no less than 25% of the total issued
share capital of the Company, satisfying the minimum percentage requirement in compliance
with Rule 8.08(1) of the Listing Rules. Based on the Offer Price of HK$35.00 per Share, the
Company will have a market capitalization of at least HK$375 million held by the public at
the time of the Listing as required under Rule 18A.07 of the Listing Rules.
The Directors confirm that, immediately following completion of the Global Offering: (i)
no placee will, individually, be placed more than 10% of the enlarged issued share capital
of the Company immediately after the Global Offering; (ii) there will not be any new
substantial Shareholder immediately after the Global Offering; (iii) the three largest public
Shareholders do not hold more than 50% of the H Shares in public hands at the time of Listing
in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least
300 Shareholders at the time of Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Friday, July
25, 2025 (Hong Kong time), provided that the Global Offering has become unconditional
and the right of termination described in the section headed “Underwriting — Hong Kong
Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination”
in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of
publicly available allocation details prior to the receipt of H Share certificates or prior to the
H Share certificates becoming valid evidence of title do so entirely at their own risk.
Assuming that the Global Offering  becomes unconditional at or before 8:00 a.m. on Friday,
July 25, 2025 (Hong Kong time), it is expected that dealings in the H Shares on the Stock
Exchange will commence at 9:00 a.m. on Friday, July 25, 2025 (Hong Kong time). The H
Shares will be traded in board lots of 100 H Shares each, and the stock code of the H Shares
will be 9887.
By order of the Board
Nanjing Leads Biolabs Co., Ltd.
ԯၪʮ̡
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer
Hong Kong, July 24, 2025
As of the date of this announcement, the board of directors of the Company named in the
Prospectus comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng
and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai
and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and
Ms. Du Jiliu as proposed independent non-executive directors.
